Immunomodulatory effects of low dose cis-Diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer

Cancer Investigation

Volumn 20, Issue 2, 2002, Pages 166-173

  Shibata, Masahiko ^a   Nezu, Takeshi ^a   Kanou, Hisao ^a   Nagata, Yasuhiko ^a   Kimura, Tomo ^a   Takekawa, Motoo ^a   Ando, Katsuyuki ^a   Fukuzawa, Masahiro ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; Interleukin 10; sIL 2R; sTNF R1; Tumor immunology

Indexed keywords

CISPLATIN; CYTOKINE; FLUOROURACIL; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; KRESTIN; PRODRUG; TEGAFUR; TUMOR NECROSIS FACTOR RECEPTOR; UFT; URACIL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CELLULAR IMMUNITY; CLINICAL ARTICLE; COLORECTAL CANCER; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; LIVER METASTASIS; LUNG METASTASIS; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR IMMUNOLOGY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-10; MALE; MIDDLE AGED; POLYSACCHARIDES, BACTERIAL; RECTAL NEOPLASMS; TEGAFUR; URACIL;

EID: 0036198678     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120001142     Document Type: Article

References (58)

1. The human interleukin-2 receptor: Normal and abnormal expression in T cells and in leukemias induced the human T-lymphotropic retroviruses
2. Peripheral blood lymphocytes from patients with cancer lack interleukin-2 receptor expression: Isolation of mRNA encoding IL-2R
3. Expression of functional IL-2 receptor by lipopolysaccharide and interferon γ stimulated human monocytes
4. The interleukin-2 receptor
5. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro
6. An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro
7. The role of tumor necrosis factor (cachectin) in cachexia
8. Identity of tumor necrosis factor and the macrophage-secreted factor cachectin
9. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: The Role of cachectin (tumor necrosis factor)
10. Two TNF receptors
11. Tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors
12. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity
13. Soluble forms of tumor necrosis factor receptors (Tnf-Rs).The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor
14. Shedding of tumor necrosis factor receptors by activated human neutrophils
15. Characterization In vitro of a human tumor necrosis factor binding protein: A soluble form of a tumor necrosis factor receptor
16. Human TNF mutants with selective activity on the P55 receptor
17. Use of a monoclonal antibodies of a human cytotoxin for its isolation and for examining the self-induction of resistance to this protein
18. Dominance of resistance to the cytocidal effect of tumor necrosis factor in heterokaryons formed by fusion of resistant and sensitive cells
19. Sensitization and desensitization to lethal effects of tumor necrosis factor and of interleukin-1
20. Increased serum concentrations of soluble tumor necrosis factor receptor I in noncachectic and cachectic patients with advanced gastric and colorectal cancer
21. Increased serum concentration of circulating soluble receptor for interleukin-2 and its effect as a prognostic indicator in cachectic patients with gastric and colorectal cancer
22. Two types of mouse helper T cells: Th2 secretes a factor that inhibits cytokine production by Th1 clones
23. Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties
24. + T cells: Specificity and function
25. Cytokine regulation of T-Cell function: Potential for therapeutic intervention
26. Biologic properties of interleukin-10
27. Human interleukin-10 can directly inhibit T-cell growth
28. Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes
29. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/C mice bearing a large MOPC-315 tumor
30. Effectiveness of murine leukemia chemotherapy according to the immune state
31. Immunomodulation by various nitrosoureas and its effect on the murine host bearing a syngeneic tumor
32. Effect of cyclophosphamide on immunological control mechanisms
33. Overcoming suppression of antitumor immune reactivity in tumor-bearing rats by treatment with bleomycin
34. Enhancement of naturally occurring human spontaneous monocyte-mediated cytotoxicity by cis-Diaminedichloroplatinum (II)
35. Enhancement of natural killer cytotoxicity by cis-Diaminedichloroplatinum (II) in vivo and in vitro
36. Treatment of advanced melanoma with cisplatin and alpha interferon
37. Phase II study of continuous IFN α2b combined with CDDP in advanced malignant melanoma
38. A phase II trial of cisplatin and interferon-alpha-2b in advanced malignant melanoma, breast carcinoma, and non-small cell lung carcinoma
39. Effects of anticancer drugs on the immune system in humans
40. Combining chemotherapy with biological response modifiers in the treatment of cancer
41. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer
42. In vitro immunomodulating effect of protein-bound polysaccharide PSK on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancer
43. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and tumor-infiltrating lymphocytes activated by PSK
44. The polysaccharide K (PSK) potentiates in vitro activation of the cytotoxic function in human blood lymphocytes by autologous tumor cells
45. Enhancement of T-cell proliferation by PSK
46. Enhancement of antitumor cytotoxicity of hepatic lymphocytes by oral administrations of PSK
47. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer
48. Heterogeneous mechanisms of human cytotoxic T lymphocyte generation I. Differential helper T cell requirement for the generation of cytotoxic effector cells from Cd8(+) precursor subpopulations
49. Converging and diverging properties of human interleukin-4 and interleukin-10
50. Disregulation in TH1 and TH2 subsets of Cd4(+) T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression
51. Production of IL-10 by melanoma cells: Examination of its role in immunosuppression mediated by melanoma
52. Cytokine gene transcription in renal cell carcinoma
53. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression
54. Selective expression of interleukin-10, interferon gamma, and granulocyte-macrophage colony stimulation factor in ovarian cancer biopsies
55. Production of interleukin-10 by human bronchogenic carcinoma
56. Radical oncologic surgery affects the circulatory levels of interleukin-10
57. Colon carcinoma cell lines stimulate monocytes and lamina propria mononuclear cells to produce IL-10
58. Identification of an iL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells